HEPA - MCAP CO - Hepion Pharmaceuticals

As a biotechnology enterprise, Hepion Pharmaceuticals (HEPA) strictly adheres to ESG environmental standards regarding waste disposal in its laboratories. The business focuses on developing small-molecule treatments for steatohepatitis, diversifying its research across various directions to minimize patent threats. This chart of current share prices, valued at , highlights financial instability resulting from a high cash burn rate in the absence of consistent sales.

Market capitalization reflects the gap between shareholders' speculative expectations and the actual scale of the enterprise. This metric is calculated as the product of the current share price and the total number of outstanding securities. Analyzing the total market value of the business allows for an assessment of the asset's liquidity. For Hepion Pharmaceuticals (HEPA), this metric illustrates the value of intellectual property during a period of research stagnation. Current price action reflects a search for a buyer or a merger amid the maintenance of remaining cash reserves.